Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinic Acid SCHEMBL22217135 | 0.94 | NR4A2 (0.45) | ALDH1A1ALOX15HPGDHSD17B10NR4A2 | |
| SCHEMBL125859 | 0.94 | NR4A2 (0.45) | ALDH1A1ALOX15HPGDHSD17B10NR4A2 | |
| SCHEMBL404782 | 0.94 | ALDH1A1 (0.56) | ALDH1A1ALOX15HPGDHSD17B10AKR1C3 | |
| SCHEMBL27533156 | 0.90 | ALDH1A1 (0.47) | ALDH1A1ALOX15HPGDHSD17B10AKR1C3 | |
| SCHEMBL5523432 | 0.87 | ALDH1A1 (0.52) | ALDH1A1ALOX15HPGDHSD17B10AKR1C3 | |
| SCHEMBL27547208 | 0.86 | ALDH1A1 (0.47) | ALDH1A1ALOX15HPGDHSD17B10AKR1C3 | |
| SCHEMBL29090806 | 0.86 | ALDH1A1 (0.47) | ALDH1A1ALOX15HPGDHSD17B10KMT2A | |
| SCHEMBL9468429 | 0.86 | ALDH1A1 (0.50) | ALDH1A1ALOX15HPGDAKR1C3KMT2A | |
| Salicylic Acid SCHEMBL27531453 | 0.85 | ALDH1A1 (0.55) | ALDH1A1ALOX15HPGDHSD17B10KMT2A | |
| SCHEMBL28630802 | 0.84 | ALDH1A1 (0.49) | ALDH1A1ALOX15HPGDHSD17B10AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111635621-A | Environment-friendly film material and preparation method and application thereof | 金晖兆隆高新科技股份有限公司 | 2020-09-08 | — | — | CN | claimed |
| CN-1728995-A | Dosage forms comprising a cetp inhibitor and an HMG-CoA reductase inhibitor | PFIZER PROD INC (US) | 2006-02-01 | — | — | CN | claimed |
| CN-1615122-A | Pharmaceutical formulation comprising bicalutamide | ASTRAZENECA UK LTD (GB) | 2005-05-11 | — | — | CN | claimed |
| CN-1545421-A | Pharmaceutical composition comprising a low-solubility and/or acid-sensitive drug and a neutralized acidic polymer | �Ʒ� | 2004-11-10 | — | — | CN | claimed |
| CN-1402629-A | Pharmaceutical compositions providing enhanced drug concentrations | PFIZER PROD INC (US) | 2003-03-12 | — | — | CN | claimed |
| CN-111635621-A | Environment-friendly film material and preparation method and application thereof | 金晖兆隆高新科技股份有限公司 | 2020-09-08 | — | — | CN | disclosed |
| CN-105722392-B | Compositions of non-nucleoside reverse transcriptase inhibitors | 默沙东公司 | 2019-07-23 | — | — | CN | disclosed |
| CN-109078015-A | The solid dosage of orexin receptor antagonists | 默沙东公司 | 2018-12-25 | — | — | CN | disclosed |
| CN-105722392-A | Compositions of non-nucleoside reverse transcriptase inhibitors | 默沙东公司 | 2016-06-29 | — | — | CN | disclosed |
| CN-105492000-A | Delayed release cysteamine bead formulations, and methods of making and using the same | RAPTOR PHARMACEUTICAL INC | 2016-04-13 | — | — | CN | disclosed |
| CN-102695413-A | Stable fatty acid formulations | MYCELL HOLDINGS LTD | 2012-09-26 | — | — | CN | disclosed |
| CN-101123951-A | Pharmaceutical dosage forms comprising a low-solubility drug and a polymer | PFIZER PROD INC (US) | 2008-02-13 | — | — | CN | disclosed |
| CN-1728995-A | Dosage forms comprising a cetp inhibitor and an HMG-CoA reductase inhibitor | PFIZER PROD INC (US) | 2006-02-01 | — | — | CN | disclosed |
| CN-1688291-A | Immediate release dosage forms containing solid drug dispersions | PFIZER (US) | 2005-10-26 | — | — | CN | disclosed |
| CN-1681479-A | Pharmaceutical compositions of semi-ordered drugs and polymers | PFIZER PROD INC (US) | 2005-10-12 | — | — | CN | disclosed |
| CN-1625397-A | Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor | PFIZER PROD INC (US) | 2005-06-08 | — | — | CN | disclosed |
| CN-1615122-A | Pharmaceutical formulation comprising bicalutamide | ASTRAZENECA UK LTD (GB) | 2005-05-11 | — | — | CN | disclosed |
| CN-1545421-A | Pharmaceutical composition comprising a low-solubility and/or acid-sensitive drug and a neutralized acidic polymer | �Ʒ� | 2004-11-10 | — | — | CN | disclosed |
| CN-1458840-A | Pharmaceutical composition of cholesteryl ester transfer protein inhibitor | PFIZER PROD INC (US) | 2003-11-26 | — | — | CN | disclosed |
| CN-1402629-A | Pharmaceutical compositions providing enhanced drug concentrations | PFIZER PROD INC (US) | 2003-03-12 | — | — | CN | disclosed |